Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986183 |
Synonyms | |
Therapy Description |
Limited information is currently available on BMS-986183, a putative antibody drug conjugate targeting Glypican-3 (GPC3) (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986183 | BMS986183|BMS 986183 | GPC3 Antibody 5 | Limited information is currently available on BMS-986183, a putative antibody drug conjugate targeting Glypican-3 (GPC3) (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02828124 | Phase Ib/II | BMS-986183 BMS-986183 + Nivolumab | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | Terminated | CAN | 3 |